alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
##### 



EXHIBIT 31.2 PURSUANT TO RULES 13a-14 AND 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934 AND
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER I, Frank W. Baier, certify that:  1.
    
    I have reviewed this annual report on Form 10-K/A of Independence
Community Bank Corp. (the Registrant);2.
    
    Based on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
report;3.
    
    Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of
the Registrant as of, and for, the periods presented in this report;4.
    
    The Registrants other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant
and have:  (a)
    
    Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
Registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the
period in which this report is being prepared;(b)
    
    Evaluated the effectiveness of the Registrants disclosure
controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such
evaluation; and(c)
    
    Disclosed in this report any change in the Registrants
internal control over financial reporting that occurred during the
Registrants most recent fiscal quarter (the Registrants fourth
fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the
Registrants internal control over financial reporting; and  5.
    
    The Registrants other certifying officer(s) and I have disclosed, based
on our most recent evaluation of internal control over financial
reporting, to the Registrants auditors and the audit committee of
Registrants board of directors (or persons performing the equivalent
functions):  (a)
    
    All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the Registrants
ability to record, process, summarize and report financial
information; and(b)
    
    Any fraud, whether or not material, that involves management
or other employees who have a significant role in the Registrants
internal control over financial reporting. Date: April 29, 2004
    /s/Frank W. BaierFrank W. BaierExecutive Vice President,
Chief Financial Officer,
Treasurer and Principal Accounting Officer
COURT OF APPEALS

EIGHTH DISTRICT OF TEXAS

EL PASO, TEXAS

MICHAEL J. BUCK, 

 

 Appellant,

v.

THE STATE OF TEXAS,

 State.

§

§

§

§

§

§

§

No. 08-16-00294-CR

Appeal from the

243rd District Court

of El Paso County, Texas 

(TC# 20160D01234)

O R D E R

The Court GRANTS the Appellant’s third motion for extension of time within which to 

file the brief until May 18, 2017. NO FURTHER MOTIONS FOR EXTENSION OF TIME TO 

FILE THE APPELLANT’S BRIEF WILL BE CONSIDERED BY THIS COURT.

It is further ORDERED that the Hon. Louis Elias Lopez, Jr., Appellant’s attorney, 

prepare the Appellant’s brief and forward the same to this Court on or before May 18, 2017.

IT IS SO ORDERED this 18th day of May, 2017.

PER CURIAM

Before McClure, C.J., Rodriguez, and Palafox, JJ.
**Exhibit 31 (b)**I, Gary Jones certify that:1. I have reviewed this quarterly report on Form 10-Q of Northland Cable PropertiesSeven Limited Partnership;2. Based on my knowledge, this quarterly report does not contain any untrue statementof a material fact or omit to state a material fact necessary to make the statementsmade, in light of the circumstances under which such statements were made, notmisleading with respect to the period covered by this quarterly report;3. Based on my knowledge, the financial statements, and other financial informationincluded in this quarterly report, fairly present in all material respects thefinancial condition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this quarterly report;4. The registrant’s other certifying officer and I are responsible for establishingand maintaining disclosure controls and procedures (as defined in Exchange Act Rules13a-15(e) and 15d-15(e)) for the registrant and we have: a) Designed such disclosure controls and procedures, or causedsuch disclosure controls and procedures to be designed under oursupervision, to ensure that material information relating to theregistrant, including its consolidated subsidiaries, is made known to us byothers within those entities, particularly during the period in which thisquarterly report is being prepared;  b) Evaluated the effectiveness of the registrant’s disclosurecontrols and procedures and presented in this report our conclusions aboutthe effectiveness of the disclosure controls and procedures, as of the endof the period covered by this report based on such evaluation; and  c) Disclosed in this report any change in the registrant’sinternal controls over financial reporting that occurred during theregistrant’s most recent fiscal quarter that has materially affected, or isreasonably likely to affect, the registrant’s internal controls overfinancial reporting; and5. The registrant’s other certifying officer and I have disclosed, based on our mostrecent evaluation of internal controls over financial reporting, to the registrant’sauditors and board of directors: a) All significant deficiencies and material weaknesses in thedesign or operation of internal controls over financial reporting, whichare reasonably likely to adversely affect the registrant’s ability torecord, process, summarize and report financial information; and  b) Any fraud, whether or not material, that involvesmanagement or other employees who have a significant role in theregistrant’s internal controls over financial reporting.**Date: 11-13-07**        /s/  GARY S. JONES   Gary S. Jones   President
<PAGE>
 
                                                                      Exhibit 12

                          EVEREN CAPITAL CORPORATION
               COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
                                 (in millions)
                                  (unaudited)
<TABLE>
<CAPTION>

                                                              Year ended December 31,
                                                1998        1997        1996        1995        1994
                                                ----        ----        ----        ----        ----
<S>                                            <C>         <C>         <C>        <C>          <C>
EARNINGS:
Pretax Income (loss)                           $115.7      $ 75.0      $107.8     $(22.0)      $(12.7)
Fixed Charges                                    65.8        47.1        45.1       68.1         58.0
                                               ------------------------------------------------------

                          Earnings             $181.5      $122.1      $152.9     $ 46.1       $ 45.3
                                               ======================================================


FIXED CHARGES:
Interest expense                               $ 54.2      $ 36.6      $ 34.0     $ 52.5       $ 44.8
Approximate portion of rental expense
 representative of an interest factor            11.6        10.5        11.1       15.6         13.2
                                               ------------------------------------------------------

                          Fixed Charges        $ 65.8      $ 47.1      $ 45.1     $ 68.1       $ 58.0
                                               ======================================================

Ratio of earnings to fixed charges                2.8         2.6         3.4       0.68         0.78
                                               ======================================================

Deficiency of earnings available to cover
 fixed charges                                 $    -      $    -      $(22.0)    $(12.7)      $    -
                                               ======================================================
</TABLE>
§ 1310.03 Persons required to keep records and file reports. ( a ) Each regulated person who engages in a regulated transaction involving a listed chemical, a tableting machine, or an encapsulating machine shall keep a record of the transaction as specified by § 1310.04 and file reports as specified by § 1310.05. However, a non-regulated person who acquires listed chemicals for internal consumption or “end use” and becomes a regulated person by virtue of infrequent or rare distribution of a listed chemical from inventory, shall not be required to maintain receipt records of listed chemicals under this section.
( b ) Each regulated person who manufactures a List I or List II chemical shall file reports regarding such manufacture as specified in § 1310.05.
( c ) ( 1 ) Each regulated person who engages in a transaction with a nonregulated person which: ( i ) Involves ephedrine, pseudoephedrine, phenylpropanolamine, or gamma hydroxybutyric acid (including drug products containing these chemicals or controlled substance); and
( ii ) Uses or attempts to use the U.S. Postal Service or any private or commercial carrier must, on a monthly basis, report to the Administration each such transaction conducted during the previous month as specified in §§ 1310.05(e) and 1310.06(k) on DEA Form 453 through the DEA Diversion Control Division secure network application.
( 2 ) Each regulated person who engages in an export transaction which: ( i ) Involves ephedrine, pseudoephedrine, phenylpropanolamine, or gamma hydroxybutyric acid (including drug products containing these chemicals or controlled substance); and
( ii ) Uses or attempts to use the U.S. Postal Service or any private or commercial carrier must, on a monthly basis, report each such transaction conducted during the previous month as specified in §§ 1310.05(e) and 1310.06(k) on DEA Form 453 through the DEA Diversion Control Division secure network application.
[54 FR 31665, Aug. 1, 1989, as amended at 56 FR 8277, Feb. 28, 1991; 61 FR 14023, Mar. 29, 1996; 67 FR 14861, Mar. 28, 2002; 68 FR 57804, Oct. 7, 2003; 70 FR 294, Jan. 4, 2005; 81 FR 97022, Dec. 30, 2016]
É permitido por lei transportar qualquer valor em dinheiro ou outros instrumentos 

monetários para dentro ou para fora dos Estados Unidos da América. Entretanto, caso 

você transporte, tente transportar ou faça transportar (pelo correio ou por quaisquer 

outros meios) numerário ou outros instrumentos monetários com valor agregado 

superior a US$ 10.000, ou valor equivalente em moeda estrangeira, de uma só vez, 

dos Estados Unidos da América para outro país ou de outro país para os Estados Unidos da América, precisa apresentar uma declaração ao Serviço de Alfândega e Proteção de Fronteiras dos EUA. Essa declaração tem o nome de Declaração de Transporte 

Internacional de Numerário ou Instrumentos Monetários (Report of International 

Transportation of Currency or Monetary Instruments), FinCEN Form 105. Além disso, 

se, nos Estados Unidos da América, você receber numerário ou instrumentos monetários com valor agregado superior a US$ 10.000 (ou valor equivalente em moeda estrangeira), de uma só vez, que lhe tenham sido transportados, enviados de um local no 

exterior pelo correio ou por qualquer meio de transporte, também deve apresentar o 

FinCEN Form 105. Esse formulário está disponível em todos os portos de entrada nos 

EUA ou partida do país, bem como na WEB em: www.fincen.gov/fin105_cmir.pdf. 

Os instrumentos monetários incluem: 

1) Numerário em moeda americana ou estrangeira; 

2) Cheques de viagem em qualquer forma que seja; 

3) Instrumentos negociáveis (títulos de crédito), incluindo 

cheques, notas promissórias e ordens de pagamento, ao portador, com endosso em branco, pagáveis a um beneficiário 

fictício ou em outra forma qualquer que permitam a transferência dos fundos a um terceiro; 

4) Instrumentos incompletos (inclusive cheques, notas promissórias e ordens de pagamento) assinadas, mas com o 

nome do beneficiário omitido; e 

5) Títulos ou ações ao portador ou em qualquer outra forma 

que permita transferir os fundos a um terceiro. 

Entretanto, o termo “instrumentos monetários” não inclui: 

1) Cheques ou ordens de pagamento pagáveis “à ordem de” 

uma pessoa determinada e que não tenham sido endossados 

ou tenham endossos em preto; 

2) Recibos de depósito; ou 

3) Conhecimentos de embarque.

A declaração é exigida pelo Currency and Foreign Transaction Reporting Act 

(PL 97-258, 31 U.S.C. 5311, et seq.), com sua redação atual. O descumprimento 

dessa exigência pode resultar em sanções civis e penais, incluindo a apreensão 

do(s) instrumento(s) monetário(s).

O site do Serviço de Alfândega e Proteção de Fronteiras dos EUA é 

www.cbp.gov/xp/cgov/toolbox/ports/.

U.S. Customs and Border Protection

Washington, D.C. 20229

CBP: Zelando pela segurança das fronteiras dos EUA

Visite o site do Serviço de Alfândega e Proteção de Fronteiras dos EUA em: 

www.cbp.gov

CBP Publication No. 0000-0503 Revised June 2006

Declaração de valores em numerário

Portuguese (Brazil)

Currency Poster_Portuguese.indd 1 9/28/2006 10:35:46 PM
# C_2019430EN.01002001.xml

| 20.12.2019 | EN | Official Journal of the European Union | C 430/20 |
| --- | --- | --- | --- |

20.12.2019

EN

Official Journal of the European Union

C 430/20

---

Corrigendum to the Statement of revenue and expenditure of the Community Plant Variety Office for the financial year 2019

(
  Official Journal of the European Union C 193 of 7 June 2019
  )

On page 4, row ‘Grand Total’, in column ‘Appropriations 2018 — Payments’:

for:

‘17 012 092’,

read:

‘17 240 000’.

---
Editorial Note on Part 161
Editorial Note: Nomenclature changes to part 161 appear at 81 FR 49896, July 29, 2016.

§ 161.30 Declaration of quantity of contents on labels for canned oysters. ( a ) For many years packers of canned oysters in the Gulf area of the United States have labeled their output with a declaration of the drained weight of oysters in the containers. Packers in other areas have marketed canned oysters with a declaration of the total weight of the contents of the container. Investigation reveals that under present-day practice consumers generally do not discard the liquid packing medium, but use it as a part of the food. Section 403(e)(2) of the Federal Food, Drug, and Cosmetic Act and the regulations thereunder require food in package form to bear an accurate label statement of the quantity of food in the container.
( b ) It is concluded that compliance with the label declaration of quantity of contents requirement will be met by an accurate declaration of the total weight of the contents of the can. The requirements of § 161.145(c), establishing a standard of fill of container for canned oysters and specifying the statement of substandard fill for those canned oysters failing to meet that standard remain unaffected by this interpretation.
**Exhibit 32**

 

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with theQuarterly Report of Pace Medical, Inc. (the “Company”) on Form 10-QSB for theperiod ended June 30, 2004 as filed with the Securities and Exchange Commissionon the date hereof (the “Report”), I, Ralph Hanson, President and Treasurer ofthe Company, being the chief executive officer and the chief financial officerof the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Reportfully complies with the requirements of section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

(2) Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 
| /s/ Ralph  Hanson                                      |   |
|--------------------------------------------------------|--------|
|                                                   |
| Ralph Hanson                                           |
| Chief  Executive Officer and  Chief Accounting Officer |
| August 23,  2004                                       |

 

----
<PAGE>

                                                                    EXHIBIT 99.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Front Range Capital Corporation (the
"Company") on Form 10-QSB for the period ending September 30, 2002 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I ,
Robert L. Beauprez, Chief Executive Officer and President of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:

         (1) The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.

/s/  Robert L. Beauprez


Robert L. Beauprez
Chairman of the Board and President
November 13, 2002
[Federal Register Volume 76, Number 2 (Tuesday, January 4, 2011)]
[Notices]
[Page 320]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-33197]


-----------------------------------------------------------------------

COMMISSION ON CIVIL RIGHTS


Agenda and Notice of Public Meeting of the Louisiana Advisory 
Committee

    Notice is hereby given, pursuant to the provisions of the rules and 
regulations of the U.S. Commission on Civil Rights (Commission), and 
the Federal Advisory Committee Act (FACA), that a State Advisory 
Committee (SAC) meeting of the Louisiana Advisory Committee to the 
Commission will convene on Tuesday, January 25, 2011 at 2 p.m. and 
adjourn at approximately 5 p.m. (CST) at Jones, Walker, Waechter, 
Poitevent, Carrere & Denegre L.L.P., 201 St. Charles Avenue, 52nd 
Floor, Waechter Room, New Orleans, LA. The purpose of the meeting is to 
continue planning a future civil rights project.
    Members of the public are entitled to submit written comments. The 
comments must be received in the regional office by February 8, 2011. 
The address is U.S. Commission on Civil Rights, 400 State Avenue, Suite 
908, Kansas City, Kansas 66101. Persons wishing to e-mail their 
comments, or to present their comments verbally at the meeting, or who 
desire additional information should contact Farella E. Robinson, 
Regional Director, Central Regional Office, at (913) 551-1400 (or for 
hearing impaired TDD 913-551-1414) or by e-mail to <a href="/cdn-cgi/l/email-protection#88eefae7eae1e6fbe7e6c8fdfbebebfaa6efe7fe"><span class="__cf_email__" data-cfemail="3553475a575c5b465a5b7540465656471b525a43">[email protected]</span></a>.
    Hearing-impaired persons who will attend the meeting and require 
the services of a sign language interpreter should contact the Regional 
Office at least ten (10) working days before the scheduled date of the 
meeting.
    Records generated from this meeting may be inspected and reproduced 
at the Central Regional Office, as they become available, both before 
and after the meeting. Persons interested in the work of this advisory 
committee are advised to go to the Commission's Web site, http://www.usccr.gov, or to contact the Central Regional Office at the above 
e-mail or street address.
    The meeting will be conducted pursuant to the provisions of the 
rules and regulations of the Commission and FACA.

    Dated in Washington, DC, on December 27, 2010.
Peter Minarik,
Acting Chief, Regional Programs Coordination Unit.
[FR Doc. 2010-33197 Filed 1-3-11; 8:45 am]
BILLING CODE 6335-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
§ 310.532 Drug products containing active ingredients offered over-the-counter (OTC) to relieve the symptoms of benign prostatic hypertrophy. ( a ) The amino acids glycine, alanine, and glutamic acid (alone or in combination) and the ingredient sabal have been present in over-the-counter (OTC) drug products to relieve the symptoms of benign prostatic hypertrophy, e.g., urinary urgency and frequency, excessive urinating at night, and delayed urination. There is a lack of adequate data to establish general recognition of the safety and effectiveness of these or any other ingredients for OTC use in relieving the symptoms of benign prostatic hypertrophy. In addition, there is no definitive evidence that any drug product offered for the relief of the symptoms of benign prostatic hypertrophy would alter the obstructive or inflammatory signs and symptoms of this condition. Therefore, self-medication with OTC drug products might unnecessarily delay diagnosis and treatment of progressive obstruction and secondary infections. Based on evidence currently available, any OTC drug product containing ingredients offered for use in relieving the symptoms of benign prostatic hypertrophy cannot be generally recognized as safe and effective.
( b ) Any OTC drug product that is labeled, represented, or promoted to relieve the symptoms of benign prostatic hypertrophy is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act), for which an approved application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved application, such product is also misbranded under section 502 of the act.
( c ) Clinical investigations designed to obtain evidence that any drug product labeled, represented, or promoted for OTC use to relieve the symptoms of benign prostatic hypertrophy is safe and effective for the purpose intended must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.
( d ) After August 27, 1990, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.
[55 FR 6930, Feb. 27, 1990]
#### § 1308.34 Exempt anabolic steroid products.

The list of compounds, mixtures, or preparations that contain an anabolic steroid that have been exempted by the Administrator from application of sections 302 through 309 and 1002 through 1004 of the Act (21 U.S.C. 822-829 and 952-954) and §§ 1301.13, 1301.22, and 1301.71 through 1301.76 of this chapter for administrative purposes only may be obtained by submitting a written request to the Drug and Chemical Evaluation Section, Drug Enforcement Administration. See the Table of DEA Mailing Addresses in § 1321.01 of this chapter for the current mailing address.

[75 FR 10679, Mar. 9, 2010]
[No. 38605-1-I.

Division One.

December 1, 1997.]

#### The State of Washington, *Respondent,*v. Ryan Mogen, *Appellant.*

Appeal from a judgment of the Superior Court for King County, No. 96-8-01378-3, Norma Smith Huggins, J., entered April 12, 1996. *Affirmed*by unpublished per curiam opinion.